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doi:10.1Objective: Aortic stenosis is an inflammatory disease, associated with increased tissue levels of interleukin-1
beta. We hypothesized that the antagonist of interleukin-1 beta, interleukin-1 receptor antagonist, is deficient
in aortic valves and that its production by aortic valve interstitial cells is less in cells from stenotic valves
than from controls.
Methods: Valve leaflets from stenotic aortic valves (n¼ 6) and from valves from hearts explanted at the time of
cardiac transplantation (n ¼ 6) were studied by immunostaining for interleukin-1 receptor antagonist. Aortic
valve interstitial cells were isolated from valves, and receptor antagonist levels were determined from cell ly-
sates (enzyme-linked immunosorbent assay). Osteogenic phenotype changes in valve cells stimulated by toll-
like receptors 2 and 4 were determined by immunoblotting for bone morphogenetic protein-2 after treatment
with and without interleukin-1 receptor antagonist (100 mg/mL). Statistics were by analysis of variance.
Results: Interleukin-1 receptor antagonist was abundant in nonstenotic aortic valve leaflets and virtually absent
in leaflets from stenotic valves. Aortic valve interstitial cells from grossly normal leaflets produced significantly
more receptor antagonist at baseline and in response to toll-like receptor 2 and 4 stimulation, than did cells from
diseased valves (P<0.05). Interleukin-1 receptor antagonist was able to significantly attenuate toll-like receptor
2, but not toll-like receptor 4, stimulated bone morphogenetic protein-2 production in aortic valve interstitial
cells (P<.05).
Conclusions: Interleukin-1 receptor antagonist–mediated mechanisms of anti-inflammation are dysfunctional
in stenotic valves. We conclude that such impaired mechanisms of anti-inflammation may contribute to the path-
ogenesis of aortic stenosis. (J Thorac Cardiovasc Surg 2011;141:481-6)E
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SCalcific aortic stenosis has traditionally been considered
a ‘‘degenerative’’ process with passive accumulation of cal-
cium on the aortic valve leaflets. However, recent studies
now suggest that calcific aortic stenosis may in fact be an
active disease process; mechanisms of inflammation and os-
teogenesis appear to play important roles in the pathogene-
sis of aortic stenosis.1-6 As such, aortic stenosis may be an
inflammatory disease.
The aortic valve interstitial cell (AVIC) has been impli-
cated in the pathogenesis of aortic stenosis.7 In response
to proinflammatory stimulation via toll-like receptors
(TLRs) 2 and 4, the phenotype of human AVICs changes
from that of a myofibroblast to that of a bone-forming–
like cell.7-10 Characteristics of this osteogenic phenotype
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The Journal of Thoracic and Caforming protein, bone morphogenetic protein-2 (BMP-2),
the osteogenic transcription factor, Runx2, and an increased
expression and activity of alkaline phosphatase.7-10
The net inflammatory state of any tissue is determined
by the relative balance of proinflammatory and anti-
inflammatory mechanisms.11 In response to proinflammatory
stimulation, a deficiency of anti-inflammatory mechanisms
will lead to unopposed actions of proinflammatory mecha-
nisms. Such an imbalance of proinflammatory and
anti-inflammatory mechanisms has been implicated in the
pathogenesis ofmany inflammatory diseases. Specifically, in-
creased tissue levels of interleukin-1 beta (IL-1b) relative to
its anti-inflammatory antagonist, interleukin-1 receptor an-
tagonist (IL-1RA), have been implicated in the pathogenesis
of rheumatoid arthritis, inflammatory bowel disease, athero-
sclerosis, and other inflammatory diseases.12
IL-1b has recently been implicated in the pathogenesis of
aortic stenosis as well.13 Produced by circulating mononu-
clear cells, the proinflammatory actions of IL-1b are medi-
ated by the membrane-bound IL-1 receptor (IL-1R).14 The
specific antagonist of IL-1b is the anti-inflammatory cyto-
kine, IL-1RA, which blocks the actions of IL-1b at its re-
ceptor.12 The balance between IL-1 and IL-1RA in
a given tissue may determine the development of inflamma-
tory disease; a deficiency of the anti-inflammatory actions
of IL-1RA relative to IL-1b leads to inflammation and tissuerdiovascular Surgery c Volume 141, Number 2 481
Abbreviations and Acronyms
AVIC ¼ aortic valve interstitial cell
BMP-2 ¼ bone morphogenetic protein-2
ELISA ¼ enzyme-linked immunosorbent assay
IL-1b ¼ interleukin-1 beta
IL-1R ¼ IL-1 receptor
IL-1RA ¼ interleukin-1 receptor antagonist
LPS ¼ lipopolysaccharide
PBS ¼ phosphate-buffered saline
PGN ¼ peptidoglycan
TLR ¼ toll-like receptor
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Sdestruction.12 Given that aortic stenosis appears to be an in-
flammatory disease and that a deficiency of IL-1RA has
been implicated in the pathogenesis of many inflammatory
diseases, we hypothesized that a deficiency of IL-1RA may
contribute to the pathogenesis of aortic stenosis as well. We
further hypothesized that the source of IL-1RA in aortic
valve leaflets is the AVIC.
In nonstenotic and stenotic aortic valve leaflets, the
purposes of this study were as follows: (1) to characterize
IL-1RA in aortic valve leaflets, (2) to examine the produc-
tion of IL-1RA by AVICs, and (3) to examine the ability
of IL-1RA to prevent the osteogenic phenotype changes of
AVICs induced by the proinflammatory activation of
TLR-2 and TLR-4. The results of this study demonstrate
the following: (1) IL-1RA is deficient in stenotic aortic valve
leaflets; (2) production of IL-1RA is significantly reduced in
AVICs from stenotic aortic valves; and (3), IL-1RA attenu-
ates the osteogenic phenotypic change of AVICs induced by
proinflammatory stimulation byTLR-2. These findings have
not previously been described and provide mechanistic
insight into the pathogenesis of aortic stenosis.MATERIALS AND METHODS
This study was approved by the Colorado Multiple Institutional Review
Board of the University of Colorado Health Sciences Center. All patients
provided written informed consent.
Cell Isolation and Culture
Stenotic aortic valves were obtained from 6 patients who underwent aor-
tic valve replacement surgery for calcific aortic stenosis (men, aged 54–77
years). Controls were nonstenotic aortic valves obtained from the explanted
hearts of patients undergoing heart transplantation at the University of Col-
orado Hospital (n¼ 6). The etiology of heart failure was idiopathic dilated
cardiomyopathy in all patients (men, aged 38–55 years). None of these pa-
tients was a previous ventricular assist device recipient. On gross examina-
tion, nonstenotic valve leaflets were thin and pliable, and their surfaces
were smooth; they were grossly normal. Microscopic examination of he-
matoxylin and eosin–stained cryosections confirmed the absence of leuko-
cytic infiltration. All stenotic valves were thick and exhibited overt
calcification. Noncalcified tissue was used for cell isolation. Small sections
of each valve were frozen in OCT solution (Triangle Biomedical Science,
Durham, NC), placed in 10% formaldehyde for histologic analysis, flash482 The Journal of Thoracic and Cardiovascular Surgfrozen for future tissue homogenization, or used for AVIC isolation. Isola-
tion was by collagenase digestion, as previously described,2 and culture
was in growth medium (Medium 199 [Lonza Walkersville, Inc, Walkers-
ville, Md] with amphotericin B, penicillin G, streptomycin, and 10% fetal
bovine serum) in an incubator supplied with 5% carbon dioxide. Cells of
passages 3 to 6 were grown to 70% to 90% confluence and subcultured
to 24-well cell culture plates for experiments. Cells of each patient were
maintained as independent cultures.
Chemicals and Reagents
Medium 199 was purchased from Lonza (Walkersville, Md). Rabbit
polyclonal antibody against human BMP-2 was obtained from ProSci (Po-
way, Calif). Mouse affinity purified antibody against human IL-1RA was
obtained from eBioscience (San Diego, Calif). Human IL-1RA DuoSet
ELISA kit was obtained from R&D Systems (Minneapolis, Minn). Re-
combinant human IL-1RAwas a generous gift from Dr Charles Dinarello
(Aurora, Colo). Collagenase and other reagents were purchased from
Sigma Chemical Co (St Louis, Mo).
AVIC Treatment
AVICs studied by enzyme-linked immunosorbent assay (ELISA) for IL-
1RA were serum-starved for 24 hours after reaching approximately 90%
confluence, treated with serum-free medium alone (controls), lipopolysac-
charide (LPS, 200 ng/mL), and peptidoglycan (PGN, 10 mg/mL). After 24
hours, the cells were washed once with cold phosphate-buffered saline
(PBS) and cell lysates were prepared with 200 mL of mammalian protein
extraction reagent (Thermo Scientific, Rockford, Ill), centrifuged for 10
minutes at 10,000 RPM, and supernatant collected. AVICs treated with re-
combinant IL-1RA (100 mg/mL) were pretreated in serum-free medium
alone (controls) or IL-1RA 1 hour before treatment with LPS or PGN
(200 ng/mL and 10 mg/mL, respectively). Cells were washed once with
cold PBS and lysed with mammalian protein extraction reagent.
Immunohistochemistry
Immunohistochemical detection of IL-1RA in aortic valve leaflets was
performed by the biotin-linked peroxidase technique. Cryosections (5 mm)
wereprepared anddried at room temperature for 2 hours. Sectionswerefixed
with 4% paraformaldehyde in PBS at room temperature for 10 minutes and
then washed with PBS. Unless indicated, all incubations were performed at
room temperature. Endogenous peroxidase activity was quenched by incu-
bating sections with 0.5% hydrogen peroxide in methanol for 10 minutes.
Sections were incubated for 1 hour with 10% goat serum in PBS to block
nonspecific binding sites. Sections were then incubated overnight at 4C
with mouse affinity purified antibody against IL-1RA (10 mg/mL in PBS
containing 10% goat serum), followed by a 60-minute incubation with bio-
tinylated goat anti-mouse immunoglobulin G (1:200 dilution with PBS con-
taining 10% goat serum) from theMouseABCStaining System (SantaCruz
Biotechnology, Santa Cruz, Calif). Subsequently, sections were washed 3
times with PBS and incubated with avidin–biotin–peroxidase complex
(1:50 dilution with PBS) for 30 minutes. After thorough washes with PBS,
color development was carried out with peroxidase substrate (0.03%
H2O2 and 0.05% diaminobenzidine in double-distilled H2O). Sections
were counterstained with hematoxylin and eosin.
Cytokine Assay
IL-1RA levels in cell lysates and culture media were determined using
a DuoSet ELISA kit per manufacturer’s instructions.
Immunoblotting
Cell lysates were separated on 4% to 20%minigels and transferred onto
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, Calif). After
blocking with 5% fat-free milk solution, BMP-2 was detected using pri-
mary antibodies to BMP-2 and then a corresponding peroxidase-linkedery c February 2011
FIGURE 1. Immunohistochemical staining of sections of both nonstenotic and stenotic aortic valves for interleukin-1 receptor antagonist (IL-1RA). A and
B, Nonstenotic aortic valve section in low power (A) and high power (B) that have been immunostained for IL-1RA (brown). The arrows show intense
positive stains throughout both the lamina fibrosa and spongiosum. C and D, Stenotic aortic valve section in low (C) and high power (B). The section is
intensely fibrotic and single positive stain in panel D is localized to a leukocyte in the lamina spongiosum.
Lee et al Evolving Technology/Basic Science
E
T
/B
Ssecondary antibody (Cell Signaling Technology, Danvers, Mass) diluted
1:5000. Blots were developed with electrochemoluminescent reagent and
exposed on x-ray film. Films were scanned, and Image J software was
used to quantitate band density.
Statistical Analysis
Data are presented as mean  standard error and compared and
analyzed by analysis of variance with a post-hoc Fisher exact test.
RESULTS
Stenotic Aortic Valves Have Lower IL-1RA Levels
Than Nonstenotic Valves
Sections of stenotic aortic valves showed marked reduc-
tion in IL-1RA expression from nonstenotic aortic valves by
immunohistochemistry. Microscopic examination of hema-
toxylin and eosin–stained cryosections showed stenotic
valves were fibrotic and exhibited overt calcification. Non-
stenotic valves were thin and had no evidence of fibrosis or
calcification. Immunohistochemical staining of nonstenotic
valves was positive diffusely for IL-1RA both in the lamina
fibrosa and spongiosum (Figure 1, A and B). Stenotic aortic
valves had considerable fibrosis and staining for IL-1RA
was virtually absent (Figure 1, C and D).
AVICs FromNonstenotic Aortic Valves Have Greater
IL-1RA Levels Than AVICs From Stenotic Valves
IL-1RA was significantly decreased in AVICs from ste-
notic aortic valves (n ¼ 6) versus nonstenotic valvesThe Journal of Thoracic and Ca(n ¼ 6). IL-1RA levels were undetectable in lysates from
untreated AVICs from stenotic valves compared with
710.2  213.6 pg/mL (P<.05) in nonstenotic AVICs. Pro-
duction of IL-1RA in response to TLR stimulation was sig-
nificantly less in AVICs from stenotic valves (Figure 2). In
samples that were treated with proinflammatory stimulation
of TLR-2 and TLR-4 with PGN and LPS, respectively, IL-
1RA levels in AVICs from stenotic aortic valves were 114.9
 86.5 pg/mL and 244.9  112.4 pg/mL, respectively.
Levels in nonstenotic AVICs after TLR-2 and TLR-4
stimulation were 1570.1  339.1 pg/mL and 1122.6 
181.8 pg/mL, respectively. Overall, there was a 6- and
10-fold increase in IL-1RA in nonstenotic valve cells over
stenotic cells after TLR-2 and TLR-4 activation, respec-
tively.
IL-1RATreatment of AVICs Decreased BMP-2
Production
Treatment of AVICs with recombinant IL-1RA decreased
the production of BMP-2 and attenuated the change to an os-
teogenic phenotype (n¼ 4, Figure 3). After 24 hours of treat-
ment with IL-1RA at 100 mg/mL, densitometric analysis of
cell lysates from immunoblots showed no significant change
in expression of BMP-2 in unstimulated cells (P<.05). Stim-
ulation of TLR-2 (PGN) in AVICs from nonstenotic valves
produced an 81.0% 9.0% increase in BMP-2 thatwas pre-
vented by IL-1RA. However, stimulation of TLR-4rdiovascular Surgery c Volume 141, Number 2 483
FIGURE 2. Intracellular interleukin-1 receptor antagonist (IL-1RA) in cell lysates of nonstenotic aortic valve interstitial cells (AVICs) and those from ste-
notic AVICs. IL-1RA levels were undetectable in AVICs from unstimulated (control) stenotic aortic valves versus their nonstenotic counterparts. After ac-
tivation of toll-like receptor 4 (TLR-4) and toll-like receptor 2 (TLR-2) with lipopolysaccharide (LPS) and peptidoglycan (PGN), respectively, there were
1.58-fold and 2.21-fold increases in IL-1RA in nonstenotic AVICs over unstimulated cells (control). In response to TLR-2 and TLR-4 stimulation, IL-1RA
production was significantly less in AVICs from stenotic valves compared with nonstenotic valves. *P<.05, stenotic AVICs versus nonstenotic AVICs.
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production that was not affected by IL-1RA.
DISCUSSION
The results of the present study demonstrate that an im-
portant mechanism of anti-inflammation is dysfunctional
in aortic stenosis. Although nonstenotic aortic valve leaflets
were found to have an abundance of IL-1RA, it was virtu-
ally absent in leaflets from stenotic aortic valves. Aortic
valve interstitial cells were found to be an important source
of IL-1RA in nonstenotic aortic valves and demonstrated
significantly increased production in response to proinflam-
matory stimulation. Conversely, IL-1RA production by
AVICs from stenotic aortic valves was significantly less
than in controls. Further, the potential role of IL-1RA as
an important anti-inflammatory defense mechanism was
demonstrated; the exogenous administration of IL-1RA sig-
nificantly attenuated the phenotypic changes induced by
proinflammatory stimulation of TLR-2. These data suggest
that impaired mechanisms of anti-inflammation, and specif-
ically a deficiency of IL-1RA, are associated with the path-
ogenesis of calcific aortic stenosis. To our knowledge, these
findings have not previously been described.
In the present study, isolated AVICs were examined in vi-
tro. A limitation of any such study is that the behavior of
cells in vitro may differ from the behavior of those in
vivo. However, we have previously reported that human484 The Journal of Thoracic and Cardiovascular SurgAVICs that have been passaged multiple times have func-
tion comparable with those of freshly isolated cells.7 A sec-
ond limitation of the present study is that it is not possible to
know whether the deficiency of the levels and production of
IL-1RA in stenotic valves preceded the clinical manifesta-
tion of aortic stenosis in the valves in vivo. Nonetheless,
the finding has important implications.
IL-1b has been implicated in the pathogenesis of many
inflammatory diseases, including aortic stenosis.5,13 At
the tissue level, the net balance between the levels of IL-
1b and IL-1RA helps determine whether inflammatory dis-
ease develops with its associated structural damage; local
overproduction of IL-1b and/or deficiency of IL-1RA may
lead to inflammatory disease. Inflammatory diseases such
as rheumatoid arthritis and inflammatory bowel disease,
among others, are thought to arise from a deficiency
of IL-1RA.12 In fact, the administration of recombinant
IL-1RA is an effective therapy for rheumatoid arthritis.
Secretory and intracellular isoforms of IL-1RA have
been identified in humans. Secretory IL-1RA is produced
and secreted by monocytes, neutrophils and macrophages.
Intracellular IL-1RA has been identified in hepatocytes,
macrophages, fibroblasts, endothelial cells, and vascular
smooth muscle cells.12 However, IL-1RA has not previ-
ously been described in human aortic valves, nor has its pro-
duction by AVICs been previously characterized. It is not
possible to know from the present study whether theery c February 2011
FIGURE 3. Bone morphogenetic protein-2 (BMP-2) expression in nonstenotic aortic valve interstitial cells (AVICs) treated with proinflammatory stimu-
lation and interleukin-1 receptor antagonist (IL-1RA). A Representative immunoblot of lysates of AVICs treated with lipopolysaccharide (LPS) and pep-
tidoglycan (PGN) after pretreatment with IL-1RA. B, Densitometric values for BMP-2 after activation of toll-like receptor 4 (TLR-4) and toll-like
receptor-2 (TLR-2) with LPS or PGN, respectively. TLR-2–stimulated BMP-2 production was blocked by IL-1RA. However, TLR-4–stimulated BMP-2
production was unaffected. *P<.05 versus control. zP<.05 IL-1RA treatment versus untreated, before PGN treatment.
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ceded the clinical development of aortic stenosis in vivo.
However, the results of the present study are consistent
with findings in other inflammatory diseases in which a de-
ficiency of IL-1RA has been implicated and suggest that di-
minished levels of IL-1RA may contribute to the
pathogenesis of human aortic stenosis Further, Isoda and
colleagues15 recently demonstrated echocardiographic evi-
dence of aortic stenosis and histologic evidence of increased
valve thickness, inflammatory infiltrates, and calcification
in mice lacking IL-1RA.
We7-10 have previously demonstrated that isolated AVICs
acquire an osteogenic phenotype when activated by
proinflammatory stimuli mediated by TLR-2 and -4. An im-
portant characteristic of this osteogenic phenotype is the
production of the bone-forming protein, BMP-2. A novel
finding of the present study was the inhibition by IL-1RA
of TLR-2–induced BMP-2 expression in AVICs. It did not
affect TLR-4–induced BMP-2 expression. Inhibition of
TLR-2 stimulation by IL-1RA has not previously been de-
scribed. Likewise, there has been no reported interactionThe Journal of Thoracic and Caof TLR-2 with the IL-1R, and we7 have previously reported
that isolated human AVICs do not produce IL-1b in re-
sponse to TLR-2 or -4 stimulation. Heretofore, the only
known action of IL-1RA has been inhibition of the IL-1R,
and for that reason, it is considered a specific antagonist
of IL-1b. This finding of the present study, however, implies
that the anti-inflammatory actions of IL-1RA may be medi-
ated by mechanisms in addition to its inhibition of IL-1R.
Further elucidation of this IL-1RA inhibition of TLR-2
stimulation requires further investigation and was beyond
the scope of the present study. Nonetheless, it highlights
the potential role of IL-1RA as an important anti-
inflammatory defense mechanism in the aortic valve.
In summary, the results of the present study demonstrated
a marked deficiency of an important anti-inflammatory cy-
tokine in aortic stenosis. Although IL-1RA was found
throughout nonstenotic aortic valve leaflets, it was virtually
absent in leaflets from stenotic aortic valves. Further, the
levels of intracellular IL-1RAwere undetectable in stenotic
AVICs from stenotic valves and were significantly lower af-
ter proinflammatory stimulation than in controls. Therdiovascular Surgery c Volume 141, Number 2 485
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Simportance of IL-1RA as an anti-inflammatory defense
mechanism in AVICs was demonstrated by its attenuation
of TLR-2–induced osteogenic phenotype changes. Previous
work has implicated mechanisms of inflammation in the
pathogenesis of aortic stenosis. The results of the present
study provide additional insight into this pathogenesis and
suggest that dysfunctional protective mechanisms of anti-
inflammation may play a role.
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